Myo-inositol trispyrophosphate (also known as OXY111A) is a synthetic allosteric effector of hemoglobin which increases the regulated oxygen releasing capacity of red blood cells. Myo-inositol trispyrophosphate is taken up by red blood cells via the band 3.1 transporter and promotes the dissociation of oxygen from hemoglobin specifically under hypoxic conditions and has the potential to prevent hypoxia without affecting the oxygen levels in the surrounding normoxic cells. In phase I/II clinical trial Myo-inositol trispyrophosphate shows encouraging results in patients with primary and secondary hepatopancreatobiliary tumors.